Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II
by Zacks Equity Research
Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
by Zacks Equity Research
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
by Zacks Equity Research
CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.
Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit
by Zacks Equity Research
The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.
Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
by Zacks Equity Research
AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.
Roche's (RHHBY) Application for PNH Drug Accepted by FDA
by Zacks Equity Research
Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.
EXEL vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids
by Zacks Equity Research
Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.
Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why
by Zacks Equity Research
Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.
Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.
Why Is Exelixis (EXEL) Up 10.6% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August
by Nalak Das
We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
by Zacks Equity Research
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Here's Why Exelixis (EXEL) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock
by Zacks Equity Research
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Exelixis (EXEL) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 40.91% and 4.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?